Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let’s stay connected!
To submit a correction request, please visit our Contact Us page.
The FDA approved the oral Janus kinase (JAK) inhibitor deuruxolitinib (Leqselvi) to treat alopecia areata, drugmaker Sun Pharmaceutical announced on Thursday. The approval stipulates use
CHICAGO — The investigational CD40 agonist mitazalimab and modified FOLFIRINOX demonstrated encouraging activity in patients with previously untreated metastatic pancreatic ductal adenocarcinoma, according to the
FDA’s latest reorganization puts a new emphasis on its investigations
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let’s stay connected!
To submit a correction request, please visit our Contact Us page.
Coca Cola KO stock analysis and is KO stock a good investment
Third JAK Inhibitor for Alopecia Areata Wins FDA Approval
The FDA approved the oral Janus kinase (JAK) inhibitor deuruxolitinib (Leqselvi) to treat alopecia areata, drugmaker Sun Pharmaceutical announced on Thursday. The approval stipulates use
Novel CD40 Agonist-Chemo Combo Shows Promise in Pancreatic Cancer
CHICAGO — The investigational CD40 agonist mitazalimab and modified FOLFIRINOX demonstrated encouraging activity in patients with previously untreated metastatic pancreatic ductal adenocarcinoma, according to the